Therapy Areas: Respiratory
Sanofi reports positive new data on nirsevimab
11 May 2022 -

French healthcare company Sanofi SA (EPA:SAN) said on Wednesday that new data analyses reinforce the efficacy of nirsevimab against respiratory syncytial virus (RSV).

Nirsevimab is an investigational long-acting antibody designed to protect all infants from birth entering their first RSV season with a single dose. It is being developed by Sanofi and biopharmaceutical company AstraZeneca plc (STO:AZN) (LON:AZN) (Nasdaq:AZN).

According to Sanofi, a prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory tract infections (LRTI), such as bronchiolitis or pneumonia, caused by RSV in infants born at term or preterm entering their first RSV season.

These findings contribute to the growing body of evidence suggesting that nirsevimab can protect all infants through their first RSV season with a single dose, the company said.